首页> 外文期刊>Circulation journal >Reduction in Morning Blood Pressure Is a Key Factor for Ameliorating Urinary Albumin Excretion in Patients With Morning Hypertension Irrespective of Treatment Regimen
【24h】

Reduction in Morning Blood Pressure Is a Key Factor for Ameliorating Urinary Albumin Excretion in Patients With Morning Hypertension Irrespective of Treatment Regimen

机译:早晨血压的降低是改善早晨高血压患者尿白蛋白排泄的关键因素,与治疗方案无关

获取原文
           

摘要

Background: ?The Morning Hypertension and Angiotensin Receptor Blocker/Hydrochlorothiazide Combination Therapy (MAPPY) study has shown that losartan/hydrochlorothiazide (HCTZ) combination is superior to high-dose losartan in not only reducing morning systolic blood pressure (SBP) but also ameliorating urinary albumin excretion (UAE) after 3-month treatment. The purpose of the present study was to investigate factors associated with UAE reduction in on-treatment patients with morning hypertension. Methods and Results: ?A total of 95 patients registered in the MAPPY study were analyzed. Patients were treated with either a losartan/HCTZ combination regimen (n=47) or a high-dose losartan regimen (n=48). Three-month treatment significantly reduced morning SBP, evening SBP, and clinic SBP (P
机译:背景:?早晨高血压和血管紧张素受体阻滞剂/氢氯噻嗪联合治疗(MAPPY)的研究表明,氯沙坦/氢氯噻嗪(HCTZ)联合治疗在降低早晨收缩压(SBP)和缓解尿道排泄方面均优于大剂量氯沙坦。 3个月的治疗后白蛋白排泄(UAE)。本研究的目的是调查与早晨高血压治疗患者中阿联酋减少相关的因素。方法和结果:总共对95例在MAPPY研究中注册的患者进行了分析。患者接受氯沙坦/ HCTZ联合方案(n = 47)或大剂量氯沙坦方案(n = 48)治疗。三个月的治疗显着降低了早上SBP,晚上SBP和临床SBP(P

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号